Quantcast
Last updated on April 21, 2014 at 9:11 EDT

Latest Goodwin Biotechnology Inc. Stories

2014-03-24 16:25:08

PLANTATION, Fla., March 24, 2014 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced an agreement with Aspyrian Therapeutics, Inc. for the technology transfer, process development, scale-up, and cGMP manufacturing of a novel Antibody Drug Conjugate (ADC) for use in Phase I clinical trials. Aspyrian Therapeutics has secured an exclusive license from the National Cancer Institute for a new ADC technology platform, Near-infrared Photoimmunotherapy (PIT), which permits highly efficient and...

2013-10-01 16:25:41

PLANTATION, Fla. and MONTREAL, Oct. 1, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced that Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, has contracted for the next phase of manufacturing activities for two of their leading drug candidates: -- AB-16B5, a monoclonal antibody which targets secreted clusterin for the inhibition of cancer-associated epithelial-to-mesenchymal...

2013-09-12 12:29:09

PLANTATION, Fla., Sept. 12, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced a key appointment that is designed to position the company for the future. SooYoung Lee, PhD has returned to Goodwin Biotechnology as Chief Operating Officer. He will report to newly appointed CEO, Karl Pinto, and will oversee all aspects of Goodwin's Contract Manufacturing Operations. SooYoung has had a distinguished career in the biological industry spanning several decades. After earning...

2013-06-03 08:29:10

PLANTATION, Fla., June 3, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) announced today the award of a sub-contract from Emergent BioSolutions for GBI to conduct some early stage proof-of-concept feasibility process development to investigate concentrating AVA filtrate for storage before the downstream process for BioThrax(®) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the protection against anthrax disease. Anthrax is a...

2013-04-25 08:35:50

PLANTATION, Fla. and LEXINGTON, Ky., April 25, 2013 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Coldstream Laboratories, Inc. have established a collaboration for developing and manufacturing high-potency, highly cytotoxic materials (e.g., small molecules, protein toxins, cytotoxic antibody drug conjugates, and other bioconjugates). "Over the last 20 years, GBI has offered cell culture and purification process development, scale-up, GLP manufacturing and cGMP manufacturing services...

2012-10-25 11:22:54

PLANTATION, Fla., Oct. 25, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) has been named a three-category winner in the 2012 CMO Leadership Awards presented by Life Science Leader magazine. GBI was rated in the top 20% for Innovation, Productivity and Regulatory. "We at GBI are honored to be recognized in three categories of the CMO Leadership Awards, and consider it a testament to the quality of our people and their dedication to our customers," noted Bansi K. Bhan, Interim CEO at...

2012-06-04 02:26:37

PLANTATION, Fla. and HOUSTON, June 4, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and The University of Texas MD Anderson Cancer Center jointly announce a collaboration for process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator. The fusion protein targets the tumor neovasculature, or blood supply, and inhibits tumor growth, and the...

2012-01-03 09:44:00

PLANTATION, Fla. and MOSCOW, Jan. 3, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and OncoMax, LLC, a Maxwell Biotech portfolio company, jointly announced an agreement for cell line engineering and manufacturing of a monoclonal antibody expressed in a mammalian cell line. The monoclonal antibody will be engineered by GBI's collaborative partner, and then GBI will evaluate the cell lines, select the highest producer and manufacture the monoclonal antibody for use and evaluation in...

2011-10-24 08:00:00

PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Spectros Corporation jointly announced a collaboration for the process development and cGMP manufacturing of an antibody: dye conjugate that will be used in Phase I and Phase II clinical trials. "The leading surgical treatment for prostate cancer is prostatectomy, or removal of the prostate," noted David Benaron, CEO at Spectros Corporation. "Unfortunately, residual tumor...

2011-06-02 09:00:00

PLANTATION, Fla. and MONTREAL, June 2, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI), a full service CMO focused on process development and GMP manufacturing of cell culture derived biopharmaceuticals, and Alethia Biotherapeutics, Inc., a biotechnology company focused on monoclonal antibody development with a very sensitive and highly disease-tissue specific proprietary target discovery platform, announced a collaboration on the development of a mammalian cell line-based IgG...